Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Roche Able to Produce More Fuzeon Than Expected

July 15, 2003

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

David Reddy, head of drug maker Roche's HIV division, today at the International AIDS Society's 2nd Conference on Pathogenesis and Treatment announced that the company expects to be able to supply 50% more of its new antiretroviral drug Fuzeon by the end of 2003 than originally expected, Reuters reports (Reuters, 7/15). The FDA on March 13 approved the drug, which is designed for HIV/AIDS patients who have failed to respond to other medications and is the first drug in seven years that uses a new method to fight the virus. Fuzeon is in a new class of drugs called fusion inhibitors, which prevent the virus from entering cells by prohibiting the virus from attaching to cell membranes. Roche and pharmaceutical company Trimeris had projected that they would be able to supply the drug worldwide to between 12,000 and 15,000 patients in 2003 and to approximately 32,000 by the end of 2004 (Kaiser Daily HIV/AIDS Report, 3/21). Roche now expects to be able to produce the drug for 18,000 patients by the end of the year and to make further manufacturing improvements by removing "production bottlenecks" at its Colorado plant, according to Reuters (Reuters, 7/15).

Back to other news for July 15, 2003


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2003 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More on HIV Medications
More News on T-20 (Enfuvirtide, Fuzeon)

Tools
 

Advertisement